As gene therapies advance toward indications with larger patient populations, adeno-associated virus (AAV) manufacturers are under growing pressure to deliver high-quality vectors at substantially ...
Recombinant adeno-associated virus (AAV) and lentiviral vectors (LV) are vehicles for direct delivery of therapeutic genes to patients' cells. In the coming years, the use of AAV and LV in clinical ...
Adeno-associated viruses (AAV) have emerged as pivotal delivery vehicles for gene therapy due to their overall safety (less immunogenic), efficiency (broad tropism), and long-term gene expression.
MADISON, Wis., Aug. 11, 2021 /PRNewswire/ -- Mirus Bio, an innovator in transfection technologies, today announces the launch of the TransIT® VirusGEN® GMP product line. This expansion to the existing ...
The project aims to demonstrate the scalability & reproducibility of Exothera's AAV production processes from small scale (1-2 L) up to 2,000L bioreactor scale. Exothera will lead the project at its ...
Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show great promise for treatment of diseases from genetic disorders to cancer.
Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results